Talphera Inc (TLPH) FinancialsTLPHTalphera Inc

Talphera Inc (TLPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DSUVIA, accounting for 88.9% of total sales, equivalent to $224.00K. Another important revenue stream is DZUVEO. Understanding this composition is critical for investors evaluating how TLPH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Talphera Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -143.36%, provide a clear picture of how effectively TLPH converts its operational activities into shareholder value.

In the context of the broader market, TLPH competes directly with industry leaders such as XLO and CLNN. With a market capitalization of $52.43M, it holds a significant position in the sector. When comparing efficiency, TLPH's gross margin of N/A stands against XLO's 100.00% and CLNN's 71.43%. Such benchmarking helps identify whether Talphera Inc is trading at a premium or discount relative to its financial performance.

Talphera has shown a concerning financial performance with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, indicating potential undervaluation but also reflecting ongoing losses. The gross margin is reported at 100% for some quarters, but the overall revenue remains low, with total revenue of only 27,000 USD in Q1 2025.